

# The multiple faces of papillomavirus

The 23<sup>rd</sup> T. B. Teoh Foundation Lecture  
Annual General Meeting, Hong Kong College of Pathology



**Paul KS Chan**


Department of Microbiology

香港中文大學醫學院


**Faculty of Medicine**  
The Chinese University of Hong Kong

# Cervical HPV






### HPV TYPE-SPECIFIC RISK ESTIMATES FOR CERVICAL CANCER



# Natural History of High-Risk HPV Infection





A painting of a woman's face, likely a portrait, set against a vibrant, abstract background of green, yellow, and pink floral patterns. The woman has dark hair and is looking directly at the viewer. The painting style is expressive and somewhat abstract, with visible brushstrokes and a rich color palette.

**How common is cervical HPV infection in Hong Kong ?**

**Should every girl receive HPV vaccine ?**

**Any high-risk group ?**

2080 women enrolled for cervical screening


Hong Kong



Average for 21-45 yr : 10.8%

~ 1 / 10

Any HPV




Chan et al. Determinants of cervical human papillomavirus infection: differences between high- and low-oncogenic risk types. *Journal of Infectious Diseases* 2002; 185: 28



1600 women enrolled for cytology screening

Macau




## 2604 healthy women in Hong Kong:

	HPV	Odds ratio
<b>No. sex partners in life-time</b>		
≤ 1	5.8%	Reference
2-3	10.3%	1.6 (1.1-2.5)
≥4	18.8%	3.2 (1.6-6.2)
<b>Smoking</b>		
No	6.2%	Reference
Yes	19.2%	3.0 (1.7-5.3)

HPV infection is **not limited** to those with more sex partners & smokers





**Any priority group ?**



# Systemic Lupus Erythematosus

	SLE patients N = 85 Mean age = 42 yr	Controls N = 2080 Mean age = 44 yr
Abnormal Pap smear	16.0%	5.7%
Squamous intraepithelial lesions	11.8%	2%
HPV (all types)	11.8%	7.3%
HPV (high-risk)	10.6%	4.2%
HPV16	4.7%	1.6%

45.5% of SLE patients with HPV (high-risk) develop SIL within 3 yr

SLE patients have impaired ability to clear high-risk HPV infection

Tam, Chan et al. Increased prevalence of squamous intraepithelial lesions in Systemic Lupus Erythematosus: Association with human papillomavirus infection. *Arthritis & Rheumatism* 2004; 50: 3619.

Tam, Chan et al. Risk factors for squamous intraepithelial lesions in Systemic Lupus Erythematosus: a prospective cohort study. *Arthritis Care & Research* 2011; 63: 269






Can HPV vaccine prevent all cervical cancers ?



High-risk  
HPVs

加衛苗




HPV 6, 11, 16, 18

卉妍康



HPV 16, 18


# Coverage of current HPV vaccines for cervical cancers in Hong Kong




120 cervical cancers, 21% adenocarcinoma

# Coinfection with multiple HPV types

## Squamous cell carcinoma




## Adenocarcinoma




- Single-type
- 2 HPV types
- 3 HPV types
- 4 or more HPV types


## CIN3



## CIN2




## CIN1




# Cumulated Attribution of HPV types to Cervical Cancers in Hong Kong

Squamous cell carcinoma (N = 339)



# Cumulated Attribution of HPV types to Cervical Cancers in Hong Kong

Adenocarcinoma (N = 105)






# Cumulated Attribution of HPV types to Cervical Intraepithelial Lesions in Hong Kong


CIN 2 (N = 805)

18.4%



CIN 3 (N = 772)

35.9%



# HPV 16/18 vaccines

Direct protection

Cross-protection

HPV 16 / 18 neoplasia

Non-HPV 16 / 18  
high-risk HPV neoplasia

~60-65% cervical cancers




~20-40% CIN 2 / 3



Additional protection

Varies between the 2 vaccines





HPV type distribution in cervical cancer






## High Prevalence of Human Papillomavirus Type 58 in Chinese Women With Cervical Cancer and Precancerous Lesions


Paul K.S. Chan,<sup>1\*</sup> Wai-Hon Li,<sup>2</sup> May Y.M. Chan,<sup>2</sup> Wei-Ling Ma,<sup>2</sup> Jo L.K. Cheung,<sup>1</sup> and Augustine F. Cheng<sup>1</sup>

<sup>1</sup>Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong

<sup>2</sup>Department of Obstetrics and Gynaecology, Queen Elizabeth Hospital, Kowloon, Hong Kong



HPV in Chinese With Cervical Lesions



# Meta-analysis on attribution of HPV58 in cervical cancers (worldwide)

No. of Studies

No. of Patients

2

129

10

1732

44

9845

10

1498

5

599

Total


71

13803

HPV58 in HPV-positive cervical cancers

4.9 (4.5-5.3)% in Asia

Significantly higher than Americas, Europe and Africa,  $P < 0.001$



# Meta-analysis on attribution of HPV58 in cervical cancer (Asia)

No. of studies

No. of Patients

2

371

5

895

8

1622


29

6957

**Total**

**44**


**9845**



HPV58 in HPV-positive cervical cancers  
 6.4 (5.9-7.0)% in Eastern Asia  
 Significantly higher than others, P < 0.001



# Prevalence of HPV58 in SCC in East Asia







**Why HPV58-cancer is more common in East Asian women ?**



Host susceptibility



HPV58 variants

**HLA DRB1\*06**

↑ HPV58 CIN3/ cancer

Odds ratio: 3.68 [1.37-9.92]


Higher oncogenicity ??

Ethno / geographical distribution ??


# HPV58 International Study

15 sites


401 HPV58 +ve samples





# Distribution of HPV58 variants



A1 rare worldwide, expect in Asia



Lineage C more common in Africa



Amino acid substitution	Normal (N = 79)	CIN3/ICC (N = 64)	p-value <sup>2</sup>	Odds ratio (95% CI) <sup>3</sup>
<b>E7</b>				
R9K	0	2	0.199	–
<b>T20I</b>	<b>15</b>	<b>27</b>	<b>0.004</b>	<b>3.11 (1.38–7.07)</b>
G41R	46	25	0.035	0.46 (0.22–0.95)
T50I	1	0	1.000	–
G63D	47	25	0.024	0.44 (0.21–0.90)
G63H	1	1	1.000	1.24 (0.00–46.34)
<b>G63S</b>	<b>18</b>	<b>27</b>	<b>0.021</b>	<b>2.47 (1.13–5.44)</b>
T74A	7	2	0.188	0.33 (0.05–1.84)
D76E	7	2	0.188	0.33 (0.05–1.84)
V77A	1	6	0.045	8.07 (0.92–182.76)

HPV58 T20I G63S

Higher oncogenic risk

Asia – 33%  
 America – 10%  
 Europe – 3%  
 Africa – 0%

HK-2 (26%)  
 7 – fold ↑ cancer risk

Chan et al. Association of HPV type 58 variant with the risk of cervical cancer. *Journal of National Cancer Institute* 2002; 94:1249.


Chan et al. Geographical distribution and oncogenic risk association of HPV type 58 E6 and E7 sequence variations *International Journal of Cancer* 2013;132:2528.





# Transformation of primary baby rat kidney cells with E7 protein







HPV58 Prototype E7



HPV58 E7 Variant: E7 T20I G63S






The image is a reproduction of the famous painting 'The Kiss' by Gustav Klimt. It depicts a man and a woman in a romantic embrace, lying on a patterned rug. The man is on the left, leaning over the woman on the right. They are surrounded by a dense, intricate pattern of gold, black, and various colors. The background is a dark, textured surface. A semi-transparent orange banner with white text is overlaid on the lower part of the painting.

**Can vaccination protect against HPV58-cancer ?**



# 1<sup>st</sup> generation vaccines



Relies on cross-protection

Bi-valent vaccine is better



## 2<sup>nd</sup> generation vaccine


## Nonavalent HPV vaccine




16




18




31




33




45




52



58




6




11

# Antibody response to quadrivalent vaccine (1<sup>st</sup> generation)



# 2<sup>nd</sup> generation vaccine

# Nonavalent HPV vaccine



**Good protection across all types ?**

**Good protection against all HPV 58 variants ?**





**Annual vaccination campaign since 2008**

**>1500 students / yr received**

**Voluntary, self-paid at a discount**

**Nursing Society 2009, CUHK**

**2009-2010**

**預防子宮頸癌疫苗注射活動**

**Cervical Cancer Prevention & Vaccination Campaign**

*It's now preventable!  
Let's act now!  
齊來預防! 請即行動!*

查詢電話 Enquire Tel: 2609 6428

網址 Web Site:  
[http://www.cuhk.edu.hk/health\\_promote\\_protect/health\\_education\\_activities.html](http://www.cuhk.edu.hk/health_promote_protect/health_education_activities.html)  
<http://ihome.cuhk.edu.hk/~b117966>

Produced by  
  
 香港中文大學

**預防子宮頸癌 - 注射疫苗 + 定期檢查**

**Cervical Cancer Prevention - Vaccination + Regular Check**

**講座簡介 Talk Introduction**

子宮頸癌已成為本港女性疾病的第五號殺手，其影響於近年逐漸明顯，而及早做好預防措施是防止患上子宮頸癌的不二法門。講座將會介紹子宮頸癌病徵及現有預防子宮頸癌疫苗的資訊。

Cervical cancer has become the fifth most common cancer in females in Hong Kong and its impact is worthy of attention. Proactively seeking preventive measures would be the most effective way for protection. The talk will provide a general view on cervical cancer and introduce the vaccines available for protection.

**2009-2010預防子宮頸癌疫苗注射活動**

**Cervical Cancer Prevention & Vaccination Campaign**

**健康講座 Health Talk**

題目 Topic:  
**子宮頸癌的預防及疫苗**  
 Cervical Cancer Prevention & Vaccines

講者 Speaker : 陳基淵教授 (中文大學微生物學系教授)  
 Prof. Paul Chan

日期 Date : 24 Sep, 2009  
 時間 Time : 5:30pm - 6:30pm  
 地點 Venue : L11, Mong Man Wai Building

**展覽會 Exhibition**

日期 Date	28-30 Sep and 2 Oct, 2009
地點 Venue	A-V Lab, Esther Lee Bldg. (ELB) 603, Dept. of Nursing

**注射日期 Vaccination Date**

第一針 1st Dose	28-30 Sep and 2 Oct, 2009
第二針 2nd Dose	28-30 Oct, 2009
第三針 3rd Dose	29-30 Mar, 2010
地點 Venue	A-V Lab, Esther Lee Bldg. (ELB) 603, Dept. of Nursing
時間 Time	11:00 - 15:00pm
費用 Fee	\$800 每劑/Per Dose

\*整個注射疫苗程序大概需時約15分鐘



香港中文大學  
健康教育及促進健康中心



香港中文大學醫學院



The Hong Kong Institute of Family Education  
香港家庭教育學院



香港醫學會沙田醫生網絡  
HKMA - Sha Tin Doctors Network



# 預防子宮頸癌 教育及疫苗接種運動

提高家長對子宮頸癌及疫苗的認識  
糾正誤解 把握保護女學童最佳時機



**Started 2011**

**1<sup>st</sup> dose free at school**

**2<sup>nd</sup> & 3<sup>rd</sup> dose at doctor's clinic at market price**

**>3000 students received**





How to improve cervical cancer screening in Hong Kong ?




## Age-specific prevalence of high-risk HPV infection in HK



Chan et al. Age distribution of HPV infection and cervical neoplasia reflects caveats of cervical screening policies. *International Journal Cancer* 2010; 126: 297




**1<sup>st</sup> high-risk HPV infection peak in Hong Kong**



Chan et al. Age distribution of HPV infection and cervical neoplasia reflects caveats of cervical screening policies. *International Journal Cancer* 2010; 126: 297


## Age distribution of CIN 2 / 3 following 1st infection peak



Chan et al. Age distribution of HPV infection and cervical neoplasia reflects caveats of cervical screening policies. *International Journal Cancer* 2010; 126: 297




## 2<sup>nd</sup> high-risk HPV infection peak in Hong Kong



Chan et al. Age distribution of HPV infection and cervical neoplasia reflects caveats of cervical screening policies. *International Journal Cancer* 2010; 126: 297




## Age distribution of CIN 2 / 3, cervical cancer following 2<sup>nd</sup> infection peak




Chan et al. Age distribution of HPV infection and cervical neoplasia reflects caveats of cervical screening policies. *International Journal Cancer* 2010; 126: 297

## Age distribution of CIN 2 / 3, cervical cancer following 2<sup>nd</sup> infection peak




Chan et al. Age distribution of HPV infection and cervical neoplasia reflects caveats of cervical screening policies. *International Journal Cancer* 2010; 126: 297



**2<sup>nd</sup> CIN 2/3 peak expected at 51-65 yr NOT observed**  
**Poor screening rate ?**  
**Poor screening sensitivity ?**




Chan et al. Age distribution of HPV infection and cervical neoplasia reflects caveats of cervical screening policies. *International Journal Cancer* 2010; 126: 297








Transformation zone




Palatine & lingual tonsils

# Changes in incidence of head & neck cancers 1973-2006, USA


NOT HPV-related sites, men




HPV-related sites, Men




NOT HPV-related sites, women




HPV-related sites, Women




**Tonsillar SCC  
Stockholm  
1970-2006,**



**Oropharyngeal SCC  
Hawaii, Iowa, Los Angeles  
1988-2004**



# No. of new cancers at anatomical sites and cellular types in which HPV is frequently found USA, 2009



## Estimated contribution of HPV:

Cervical cancer: ~100%

Anal cancer: 90%

Oropharyngeal cancer: >60%

Vagina, vulva, penile ~40%



# THE LANCET Oncology

Volume 11, Issue 8, August 2010, Pages 781–789



## HPV-associated head and neck cancer: a virus-related cancer epidemic

*Shanthi Marur, Gypsyamber D'Souza, William H Westra, Arlene A Forastiere*

A rise in incidence of oropharyngeal squamous cell cancer—specifically of the lingual and palatine tonsils—in white men younger than age 50 years who have no history of alcohol or tobacco use has been recorded over the past decade. This malignant disease is associated with human papillomavirus (HPV) 16 infection. The biology of HPV-positive oropharyngeal cancer is distinct with P53 degradation, retinoblastoma RB pathway inactivation, and P16 upregulation.

*Lancet Oncol* 2010; 11: 781–89


Published Online

May 6, 2010


DOI:10.1016/S1470-

2015(10)781-6

## Incidence of head & neck cancers in Hong Kong 1983 - 2011







**How common is oral HPV infection in Hong Kong ?**





Heterosexual  
men

N = 201



Homosexual  
men

N = 149



Commercial  
sex worker

N = 100

HPV

Oral

4.5%

5.4%

3.0%

Peri-anal

8.0%

32.2%

Penile

17.4%

10.1%

29.0%

cervical





Heterosexual  
men

N = 201



Homosexual  
men

N = 149



Commercial  
sex worker

N = 100




HPV

Oral

4.5%

5.4%

3.0%



# HPV Infection in Men (HIM) study

Lancet 2013; 382: 877




Brazil, Mexico, USA

1626 men, age 18-73 yr, healthy, HIV-negative

HPV test every 6 month

4.4% acquired oral HPV (all types) / yr  
1.7% acquired oral **oncogenic** HPV / yr



Acquisition rate of oncogenic HPV / 1000 person-months

Oral: 2.5

Genital : 22.2

Anal : 3.7



# HPV Infection in Men (HIM) study

Lancet 2013; 382: 877




Brazil, Mexico, USA

1626 men, age 18-73 yr, healthy, HIV-negative

HPV test every 6 months

Clearance :  
Most cleared < 1 yr  
Similar across HPV groups







**What proportion of oropharyngeal cancers are associated with HPV ?**



2005-2009

9 HA hospitals

141 oropharyngeal squamous cell carcinoma


HPV16 - 97%

HPV18 - 3%

HPV E6 mRNA + 100%

p16 + 100% (15% in HPV -ve cases)

p53 + 3% (53% in HPV -ve cases)



## Features of HPV + oropharyngeal squamous cell carcinoma

	HPV + N = 31	HPV - N = 110	P - value
< 50 yr	29%	11%	0.01
Female	26%	9%	0.01
Non-smoker	45%	14%	< 0.01
Non-drinker	59%	25%	< 0.01


## Features of HPV + oropharyngeal squamous cell carcinoma

	HPV + N = 31	HPV - N = 110	P - value
Early T stage (T1)	39%	11%	< 0.01
Basaloid differentiation	36%	7%	< 0.01
Lack keratinization	77%	45%	< 0.01
Lymphocyte infiltration	59%	25%	< 0.01



## Features of HPV + oropharyngeal squamous cell carcinoma




Overall survival of 141 OPSCC patients



Mean survival:  
 HPV + 73 months  
 HPV - 36 months

# Oropharyngeal cancer (squamous cell carcinoma) in Hong Kong 2001-2011





# Acknowledgements



## **Funding support:**

- International Centre for Genetic Engineering and Biotechnology, Italy
- The CUHK Focused Investment Scheme Funding to Centre for Microbial Genomics and Proteomics
- Research Grant Council
- Research Fund for the Control of Infectious Diseases

## **International HPV58 Study Group:**

Jong-Sup Park (Korea)  
Karen K. Smith-McCune (Africa)  
Joel M. Palefsky (USA)  
Ryo Konno (Japan)  
Lucia Giovannelli (Italy)  
Francois Coutlée (Canada)  
Samantha Hibbitts (Great Britain)  
Tang-Yuan Chu (Taiwan)  
Wannapa Settheetham-Ishida (Thailand)  
María Alejandra Picconi (Italy)  
Annabelle Ferrera (Honduras)  
Federico De Marco (Italy)  
Yin-Ling Woo (Wales)  
Tainá Raiol (Brazil)  
Patricia Piña-Sánchez (Mexico)

## **Int' Centre for Genetic Engineering & Biotechnology, Trieste, Italy**

Lawrence Banks  
David Pim



# Acknowledgements



## Gynaecologists:

### *Prince of Wales Hospital*

TH Cheung, Keith Lo, SF Yim, YF Wong, WH Tam

### *Queen Elizabeth Hospital*

May Chan, William Li, Irene Hon, Teresa Ma  
TN Yau, SM Wong, CW Yau

## Rheumatologists:

### *Prince of Wales Hospital*

LS Tam  
Edmund Li

## Sexually Transmitted Disease Specialists:

### *Department of Health*

KM Ho  
NM Luk

## ENT surgeons:

### *Yan Chai Hospital*

Eddy Lam

### *Prince of Wales Hospital*

Alexander Vlantis, CA van Hasselt

# Acknowledgements



## **Pathologists:**

### ***Prince of Wales Hospital***

Alexander Chang, May Yu, Amy Chan, KF To

### ***Queen Elizabeth Hospital***

Alexander Chan, Polly Lam, LC Ho

### ***Caritas Medical Center***

CS Ng, Stephen Lo

### ***Kwong Wah Hospital***

SK Chan

## **Pathologists:**

### ***Princess Margaret Hospital***

MC To

### ***Pamela Youde Nethersole Eastern Hospital***

WL Tang

### ***United Christian Hospital***

CY Leung

## Laboratory Team & Students



2007



2014

## The great father of HK pathologists



▲ *Dr Teoh: 2nd from left.*